30day notice

79300

Federal Register / Vol. 89, No. 188 / Friday, September 27, 2024 / Notices

Date: November 26, 2024.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G56,
Rockville, MD 20892 (Video Assisted
Meeting).
Contact Person: Maryam Rohani, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G56, Rockville, MD
20892, (301) 761–6656, maryam.rohani@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: September 23, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–22139 Filed 9–26–24; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings

lotter on DSK11XQN23PROD with NOTICES1

Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Chemical Probes and Drugs for Modulating
HIV Transcription in the Context of
Substance Use Disorders.
Date: October 21, 2024.
Time: 1:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Meysam Yazdankhah,
M.D., Scientific Review Officer, Scientific
Review Branch, Division of Extramural
Research, National Institute on Drug Abuse,

VerDate Sep<11>2014

17:09 Sep 26, 2024

Jkt 262001

NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 402–6965,
meysam.yazdankhah@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Mechanistic Research on Neuromodulation
for SUD Treatment + Using Neuromodulation
to Characterize the Continuum of
Pathophysiology Between Substance Use and
Mental Health.
Date: November 18, 2024.
Time: 11 a.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Ipolia R. Ramadan, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 827–4471,
ramadanir@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: September 23, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–22137 Filed 9–26–24; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center For Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Biological Chemistry
and Macromolecular Biophysics
Integrated Review Group,
Macromolecular Structure and Function
B Study Section, October 22, 2024,
08:30 a.m. to October 23, 2024, 08:00
p.m., National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD, 20892 which was
published in the Federal Register on
September 23, 2024, FR Doc. No. 2024–
21617, 89 FR 77533.
This meeting is being amended to
change the start time of the meeting
from 8:30 a.m. to 9:00 a.m. The meeting
is closed to the public.

PO 00000

Frm 00075

Fmt 4703

Sfmt 4703

Dated: September 23, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–22141 Filed 9–26–24; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request; Inclusion
Enrollment Form (Office of the
Director)
AGENCY:

National Institutes of Health,

HHS.
ACTION:

Notice.

In compliance with the
requirement of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 30-days of the date of this
publication.
SUMMARY:

Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection
plans and instruments, submit
comments in writing, or request more
information on the proposed project,
contact: Ms. Mikia P. Currie, Program
Analyst, Office of Policy for Extramural
Research Administration, 6705
Rockledge Drive, Suite 350, Bethesda,
Maryland 20892, or call a non-toll-free
number 301–435–0941 or email your
request, including your address to
ProjectClearanceBranch@mail.nih.gov.
Formal requests for additional plans and
instruments must be requested in
writing.
ADDRESSES:

This
proposed information collection was
previously published in the Federal
Register on July 23, 2024, pages 59746–
59747 (89 FR 59746) and allowed 60
days for public comment. No public
comments were received. The purpose

SUPPLEMENTARY INFORMATION:

E:\FR\FM\27SEN1.SGM

27SEN1

79301

Federal Register / Vol. 89, No. 188 / Friday, September 27, 2024 / Notices
of this notice is to allow an additional
30 days for public comment.
The Office of the Director, Office of
Extramural Research (OER), National
Institutes of Health (NIH), may not
conduct or sponsor. The respondent is
not required to respond to, an
information collection that has been
extended, revised, or implemented on or
after October 1, 1995, unless it displays
a currently valid Office of Management
and Budget (OMB) control number.
In compliance with section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, NIH has
submitted to OMB a request for review

and approval of the information
collection listed below.
Proposed Collection Title: The
Inclusion Enrollment Report Form,
OMB 0925–0770, Expiration Date 09/30/
2024; Extension, Office of the Director
(OD), National Institutes of Health
(NIH).
Need and Use of Information
Collection: NIH’s Office of Extramural
Research (OER) Office of Policy and
Extramural Research Administration
(OPERA) is renewing The Inclusion
Enrollment Report Form without
change. The Inclusion Enrollment
Report Form is used for all applications

involving NIH-defined clinical research.
This form is used to report both planned
and cumulative (or actual) enrollment
and describes the sex/gender, race, and
ethnicity of the study participants.
Since the last OMB approval, there has
been no change to NIH policies on the
inclusion of clinical research
participants.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
203,664.

ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses per
respondent

Average
burden per
response
(in hours)

Total annual
burden hours

Type of respondent

Inclusion Enrollment Report Form ......

Grant Applicant/Recipient ...................

67,888

1

3

203,664

Total .............................................

.............................................................

......................

67,888

....................

203,664

Dated: September 23, 2024.
Lawrence A. Tabak,
Principal Deputy Director, National Institutes
of Health.
[FR Doc. 2024–22235 Filed 9–26–24; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; 30-Day Comment
Request; Federally Funded Research
Development Center Contract
Administration System (FCAS) Vendor
Portal National Cancer Institute (NCI)
AGENCY:

National Institutes of Health,

HHS.
ACTION:

Notice.

In compliance with the
requirement of the Paperwork
Reduction Act of 1995 to provide an
opportunity for public comment on
proposed data collection projects, the
National Institutes of Health, National
Cancer Institute (NCI) will publish
periodic summaries of proposed
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 60 days of the date of this
publication.
SUMMARY:

lotter on DSK11XQN23PROD with NOTICES1

Number of
respondents

Form name

Written comments and
recommendations for the proposed

ADDRESSES:

VerDate Sep<11>2014

17:09 Sep 26, 2024

Jkt 262001

information collection should be sent
within 30 days of publication of this
notice to https://www.reginfo.gov/
public/do/PRAMain. Find this
particular information collection by
selecting ‘‘Currently under 30-day
Review—Open for Public Comments’’ or
using the search function.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection
plans and instruments, submit
comments in writing, or request more
information on the proposed project,
contact Scott Keasey, 428 Miller Drive,
Suite 59 9742, Rockville, MD 20880, or
call non-toll-free number 301–846–1115
or Email your request, including your
address to: scott.keasey@nih.gov.
Formal requests for additional plans and
instruments must be requested in
writing.
This
proposed information collection was
previously published in the Federal
Register on June 4, 2024, 89 FR 47970
and allowed 60 days for public
comment. No public comments were
received. The purpose of this notice is
to allow an additional 30 days for public
comment. The National Cancer Institute
(NCI), National Institutes of Health, may
not conduct or sponsor, and the
respondent is not required to respond
to, an information collection that has
been extended, revised, or implemented
on or after October 1, 1995, unless it
displays a currently valid OMB control
number.
In compliance with section
3507(a)(1)(D) of the Paperwork

SUPPLEMENTARY INFORMATION:

PO 00000

Frm 00076

Fmt 4703

Sfmt 4703

Reduction Act of 1995, the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below.
Proposed Collection Title: Federally
Funded Research Development Center
Contract Administration System (FCAS)
Vendor Portal National Cancer Institute
(NCI), 0925–0773, Expiration Date 10/
31/2024, REVISION, National Cancer
Institute (NCI), National Institutes of
Health (NIH).
Need and Use of Information
Collection: This is a request for OMB to
approve the revised information
collection for the Federally Funded
Research Development Center Contract
Administration System (FCAS) Vendor
Portal. The National Cancer Institute
(NCI) Office of Acquisitions (OA),
located within the Office of the Director
(OD) in the Office of Management (OM)
at the National Cancer Institute (NCI),
awards and administers contracts and
simplifies acquisitions in support of the
Institute’s mission to prevent, diagnose
and treat cancer. During the acquisition
process, the OA ensures that customer
service is paramount and
communications are open and
continuous. Currently, requests and
correspondence are sent to and received
from vendors through email, except the
FFRDC Contractor, who submits
through the FCAS Vendor Portal, which
is in production. To streamline
processes, increase transparency, and
gain efficiencies, the OA uses the FCAS
vendor portal to replace processes

E:\FR\FM\27SEN1.SGM

27SEN1